Scholars@Duke publication: Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant

Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant

Publication , Conference

Ark, JI; Nyberg, W; Simon, K; Rosales, A; Clouden, S; Eyquem, J; Asokan, A

Published in: MOLECULAR THERAPY

2022

MOLECULAR THERAPY

1525-0024

1525-0016

2022

425 / 426

APA

Chicago

ICMJE

MLA

NLM

Ark, J. I., Nyberg, W., Simon, K., Rosales, A., Clouden, S., Eyquem, J., & Asokan, A. (2022). Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant. In MOLECULAR THERAPY (Vol. 30, pp. 425–426).

Ark, Jonathan I., William Nyberg, Katherine Simon, Alan Rosales, Sylvanie Clouden, Justin Eyquem, and Aravind Asokan. “Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant.” In MOLECULAR THERAPY, 30:425–26, 2022.

Ark JI, Nyberg W, Simon K, Rosales A, Clouden S, Eyquem J, et al. Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant. In: MOLECULAR THERAPY. 2022. p. 425–6.

Ark, Jonathan I., et al. “Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant.” MOLECULAR THERAPY, vol. 30, no. 4, 2022, pp. 425–26.

Ark JI, Nyberg W, Simon K, Rosales A, Clouden S, Eyquem J, Asokan A. Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant. MOLECULAR THERAPY. 2022. p. 425–426.

MOLECULAR THERAPY

1525-0024

1525-0016

2022

425 / 426